Zacks Research Issues Positive Outlook for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Research analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a report issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $1.00 per share for the quarter, up from their previous estimate of $0.86. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's FY2027 earnings at $4.78 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. The business had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%.

Several other brokerages have also recently commented on BMRN. Wedbush reissued an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Oppenheimer upgraded BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price for the company in a report on Monday, February 24th. Cantor Fitzgerald restated an "overweight" rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Scotiabank boosted their target price on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a report on Thursday, February 20th. Finally, Piper Sandler upped their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Remove Ads

BioMarin Pharmaceutical Stock Down 0.0 %

Shares of NASDAQ BMRN traded down $0.03 during trading hours on Friday, hitting $71.52. The stock had a trading volume of 1,167,710 shares, compared to its average volume of 1,771,381. The company has a market capitalization of $13.64 billion, a P/E ratio of 32.51, a P/E/G ratio of 0.61 and a beta of 0.33. The firm's 50-day moving average price is $66.31 and its two-hundred day moving average price is $68.51. BioMarin Pharmaceutical has a 52 week low of $60.63 and a 52 week high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33.

Institutional Trading of BioMarin Pharmaceutical

Large investors have recently bought and sold shares of the stock. Merit Financial Group LLC bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at $317,000. Assenagon Asset Management S.A. grew its holdings in shares of BioMarin Pharmaceutical by 461.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock worth $40,205,000 after purchasing an additional 502,695 shares during the last quarter. Wedmont Private Capital bought a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth $430,000. Swedbank AB grew its holdings in shares of BioMarin Pharmaceutical by 11.2% during the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after purchasing an additional 43,593 shares during the last quarter. Finally, EULAV Asset Management grew its holdings in shares of BioMarin Pharmaceutical by 12.9% during the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company's stock worth $9,208,000 after purchasing an additional 15,000 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 1.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.